CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19

PHASE2CompletedINTERVENTIONAL
Enrollment

115

Participants

Timeline

Start Date

November 19, 2020

Primary Completion Date

April 28, 2021

Study Completion Date

April 28, 2021

Conditions
COVID-19 Infection
Interventions
DRUG

Brequinar

Dihydroorotate dehydrogenase inhibitor (DHODHi)

DRUG

Placebo

Placebo capsules

Trial Locations (14)

28112

Monroe Biomedical Research, Monroe

28401

Wilmington Health, Wilmington

29303

VitaLink Research, Spartanburg

29615

VitaLink - Gaffney, Gaffney

29646

Self Regional Healthcare Research Center - Self Medical Group, Greenwood

33166

Doral Medical Research, Doral

35209

Central Alabama Research, Homewood

37067

Clinical Trials Center of Middle Tennessee, Franklin

43215

Remington-Davis, Inc., Columbus

43617

Toledo Institute of Clinical Research, Toledo

78504

Centex Studies, Inc. - McAllen, McAllen

84117

Synexus Clinical Research US, Inc. - Olympus Family Medicine, Salt Lake City

90806

Ark Clinical Research, Long Beach

08244

South Jersey Infectious Disease, Somers Point

Sponsors
All Listed Sponsors
lead

Clear Creek Bio, Inc.

INDUSTRY